Kratos CEO sells 300,000 shares under trading plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kratos Defense & Security Solutions, Inc. President & CEO Eric M. DeMarco reported indirect sales by trust of a total of 300,000 shares of common stock on August 14, 2026, in multiple open-market transactions at weighted average prices in the low-to-mid $60s per share. These trades were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026 and modified on May 15, 2026. As of August 14, 2026, he also had 761,632 shares (indirect) and 63,036 shares (direct) reported as owned, plus 745,000 vested deferred RSUs and 750,000 unvested RSUs that each represent a contingent right to receive one share of common stock.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 19,638 | $63.3317 | $1.24M |
| Sale | Common Stock F1, F3 | 266,316 | $64.3321 | $17.13M |
| Sale | Common Stock F1, F4 | 4,946 | $65.0538 | $322K |
| Sale | Common Stock F1, F5, F6 | 9,100 | $66.1729 | $602K |
| holding | Common Stock F6, F7 | -- | -- | -- |
Footnotes (7)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 6, 2026 and modified on May 15, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.77 to $63.76 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.77 to $64.76 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.77 to $65.68 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.89 to $66.88 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F6. In addition to the 761,632 shares and 63,036 shares reported in Column 5, as of August 14, 2026, 745,000 deferred restricted stock units (RSUs) granted to Mr. DeMarco, representing non-qualified deferred compensation, have vested but remain subject to a previously agreed to 5-year deferral period before issuance and release, which substantially all subject RSUs are scheduled to be released by January 2029, and an additional 750,000 RSUs granted to Mr. DeMarco are currently unvested and will only vest upon achievement of applicable vesting terms described in our proxy statement on Schedule 14A filed with the SEC on April 2, 2026. Each RSU represents a contingent right to receive one share of the Company's common stock.
- F7. Includes 43,925 shares purchased through Issuer's Employee Stock Purchase Plan and approximately 19,111 shares held through Issuer's 401(k) Plan.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
deferred restricted stock units financial
non-qualified deferred compensation financial
Employee Stock Purchase Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did KTOS CEO Eric DeMarco report on this Form 4?
Were the KTOS insider sales by Eric DeMarco under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.